- Minaris has joined the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner (IRP) Program.
- The company will provide cell and gene therapy CDMO services across the development lifecycle to CIRM-funded researchers and companies.
Minaris, a global cell and gene therapy (CGT) contract development and manufacturing organisation (CDMO) and multimodality biosafety testing provider, has joined the California Institute for Regenerative Medicine (CIRM) Industry Resource Partner (IRP) Program. The announcement confirms that the company will serve as a resource to CIRM-funded researchers and companies.
Through the IRP Program, Minaris will provide Cell & Gene Therapy CDMO services spanning early-stage development to commercial manufacturing. Its capabilities include viral vector development and manufacturing, cell and gene therapy process development, clinical and commercial contract manufacturing, and biosafety and potency testing services.
The CIRM Industry Resource Partner Program connects CIRM-funded projects with experienced service providers. The aim is to help accelerate development timelines, strengthen manufacturing and quality strategies, and support the progression of regenerative medicine programmes.
“CIRM plays a critical role in advancing CGT and accelerating therapies to patients. By joining the Industry Resource Partner Program, we look forward to supporting CIRM’s network with flexible, scalable solutions tailored to the unique needs of emerging and growing cell and gene therapy programs that need to reach patients quickly and efficiently while planning for commercial success.”
Eytan Abraham, CTO and CCO of Minaris
Minaris stated that its end-to-end service model is designed to reduce development risk, streamline technology transfer, and support progression from preclinical studies through late-stage clinical trials and commercialisation.
